| Variable | Value |
|---|---|
| Age (years) | 72 (70.0-76.0) |
| Male/female, n (%) | 39 (45.9) / 46 (54.1) |
| BMI (kg/m2) | 22.4 (20.5-24.3) |
| GNRI | 95.4 (89.5-101.8) |
| Brinkman Index | 15.0 (0-765) |
| NAC, n (%) | 73 (85.9) |
| CCI, n (%) | |
| Low | 22 (25.9) |
| Middle | 54 (63.5) |
| High | 9 (10.6) |
| Clinical stage, n (%) | |
| I | 5 (5.9) |
| II | 80 (94.1) |
| Grip strength (%) | 40 (34.6-41.4) |
| KES (N/kg) | 3.25 (2.74-3.33) |
| 6MWD (m) | 430 (390.0-470.0) |
| Clinical Frailty Scale | 3 (2-3.25) |
| Pulmonary function | |
| FEV1% (%) | 76.6 (69.9-81.1) |
| %VC (%) | 107.4 (93.4-117.9) |
| Hb (g/dL) | 11.4 (10.6-11.9) |
| TP (g/dL) | 6.3 (6.0-6.6) |
| Alb (g/dL) | 3.6 (3.2-3.8) |
| Surgical procedure | |
| PD/DP, n (%) | 50 (58.8) / 35 (41.2) |
| Operative time (min) | 321.0 (253.0-399.0) |
| Infusion volume (ml) | 3010.0 (2110.0-4255.0) |
| Blood loss (ml) | 320.0 (150.0-565.0.3) |
| Complications, n (%) | 15 (20.8) |
| 6MWD-CCI Low-risk | 2 (13.3) |
| Middle-risk | 9 (60.0) |
| High-risk | 4 (26.7) |
| LOS（days） | 21.0 (17.0-28.0) |
| Model 1 | Model 2 | ||||
|---|---|---|---|---|---|
| n | HR (95% CI) | p-value | HR (95% CI) | p-value | |
| 6MWD | |||||
| ≧400 | 60 | Ref. | Ref. | ||
| < 400 | 25 | 2.80 (1.26-6.22) | 0.01 | 2.45 (0.94-6.37) | 0.066 |
| CCI | |||||
| Low | 22 | Ref. | Ref. | ||
| Middle | 54 | 3.21 (0.91-11.27) | 0.07 | 2.37 (0.70-8.09) | 0.167 |
| High | 9 | 7.25 (1.69-31.0) | < 0.01 | 4.55 (1.04-19.97) | 0.045 |
| 6MWD-CCI | |||||
| Low-risk | 19 | Ref. | Ref. | ||
| Middle-risk | 48 | 9.83 (1.27-76.32) | 0.029 | 6.79 (1.04-59.46) | 0.043 |
| High-risk | 18 | 15.20 (1.88-108.6) | 0.011 | 10.07 (1.18-85.74) | 0.035 |
